

Agenda – Day 1



TIME (CET)	SESSION
13:30–14:00	ARRIVALS AND COFFEE
14:00–14:20	WELCOME AND INTRODUCTION <ul style="list-style-type: none">• Incyte: Pivotal science – <i>Jonathan Dickinson</i>• We are ONE: Celebrating our shared successes in CML – <i>Gianantonio Rosti & Valentín García-Gutiérrez</i>
14:20–15:20	TREATMENT OPTIONS AFTER ONE 2G TKI: UPDATES IN CML <ul style="list-style-type: none">• Recent highlights and clinical updates in CML – <i>Jane Apperley</i>• Case studies: How I select a TKI and optimise dose in patients who have failed a 2G TKI – <i>Elias Jabbour</i>• Q&A
15:20–16:20	ONE SHARED EXPERIENCE: REAL-WORLD DATA FROM REGISTRIES EXPLORING TKI USE IN CML <ul style="list-style-type: none">• A retrospective analysis of patients treated with ponatinib from Italian registries – <i>Massimo Breccia</i>• A 5-year analysis of ponatinib treatment from a Belgian registry – <i>Dominiek Mazure</i>• TOPASE, an observational study of patients treated with ponatinib from 42 CML centres in France – <i>Emilie Cayssials</i>• Q&A
16:20–16:35	COFFEE BREAK
16:35–17:35	ONE GOAL: OVERCOMING TREATMENT CHALLENGES IN CML <p>Discussing patient scenarios submitted by your peers and sharing experiences to overcome treatment challenges today – <i>Gianantonio Rosti & Valentín García-Gutiérrez</i></p>
17:35–17:40	CLOSE DAY 1



Agenda – Day 2



TIME (CET)	SESSION
08:30–09:00	ARRIVALS AND COFFEE
09:00–09:05	WELCOME BACK – Gianantonio Rosti & Valentín García-Gutiérrez <ul style="list-style-type: none">Beyond the clinic: A patient's perspective on living with CML
09:05–09:50	MONITORING RESPONSE IN PATIENTS WITH CML: ONE OPPORTUNITY TO SECURE LASTING OUTCOMES <ul style="list-style-type: none"><i>BCR::ABL1</i> transcript monitoring to enable rapid decision making: Milestone measurements versus kinetics – Simona SoveriniCase studies: My experience treating CML patients with a TKI that has pan-mutational coverage after failure of a 2G TKI – Dragana MilojkovicQ&A
09:50–10:55	ONE TEAM: WORKING TOGETHER TO OPTIMISE CARE FOR PATIENTS WITH CML <ul style="list-style-type: none">Meet the multidisciplinary experts – Paolo Tarsia (pulmonologist); Rudolf Kirchmair (cardiologist); Pietro Sollena (dermatologist)Q&A
10:55–11:10	COFFEE BREAK
11:10–12:10	ONE TEAM: EXPLORING THE PATIENT JOURNEY IN CML THROUGH THE MDT <ul style="list-style-type: none">Your opportunity to engage with key members of the MDT and overcome challenges in patient management – Paolo Tarsia (pulmonologist); Rudolf Kirchmair (cardiologist); Pietro Sollena (dermatologist)
12:10–12:20	MEETING CLOSE